From the time of the original description of Parkinson’s disease (PD)1 until the 1960s, the pharmacotherapy of PD was not too complex a matter: anticholinergics were the cornerstone of treatment. The introduction of levodopa in the 1960s and the proof of its effectiveness in the treatment of PD2 have resulted in vastly improved quality of life and reduction of disability in PD patients. Today, there are many choices in the initial pharmacological treatment of early PD,3-9 each having its own strengths and weaknesses. The goal of this chapter is to provide a sound rationale for initial pharmacotherapy in early PD, based upon current scientific evidence and personal experience.
ASJC Scopus subject areas